Streetbeat News

Price Targets

CTLT

Jefferies analyst David Windley downgrades Catalent (NYSE:CTLT) from Buy to Hold and lowers the price target from $45 to $44.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:40 am

MYTE

Jefferies analyst Flavio Cereda downgrades MYT Netherlands Parent (NYSE:MYTE) from Buy to Hold and lowers the price target from $19 to $4.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:39 am

BLDP

BMO Capital analyst Ameet Thakkar downgrades Ballard Power Systems (NASDAQ:BLDP) from Market Perform to Underperform and lowers the price target from $4.5 to $4.25.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:38 am

FOUR

MoffettNathanson analyst Eugene Simuni upgraded Shift4 Payments (NYSE:FOUR) from Market Perform to Outperform and raised the price target from $75 to $80.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:37 am

MAXN

Roth MKM analyst Philip Shen upgrades Maxeon Solar Technologies (NASDAQ:MAXN) from Neutral to Buy and raises the price target from $21 to $40.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:33 am

EL

Berenberg analyst Fulvio Cazzol assumes Estee Lauder Cos (NYSE:EL) with a Buy rating and announces a price target of $243.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:32 am

IPGP

Raymond James analyst Brian Gesuale upgraded IPG Photonics (NASDAQ:IPGP) from Market Perform to Outperform and announced a $170 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:30 am

AKBA

HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:22 am

ATRA

HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Atara Biotherapeutics (NASDAQ:ATRA) and raises the price target from $27 to $28.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:21 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 10:20 am